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1166-209 Long-Term Sensitivity and Positive Predictive Value of 
Symptoms as an Index of Atrial Tachyarrhythmia 
Recurrence in Paced Patients: A Report of Device-
Based Monitoring in the Natural History of Atrial 
Fibrillation Trial
Adam Strickberger, John Ip, Sanjeev Saksena, Kenneth Curry, Tristram Bahnson, 
Douglas Hettrick, Paul Ziegler, Univeristy of Michigan, Ann Arbor, MI
Background: The short-term reliability of patient reported symptoms as a marker of
atrial tachyarrhythmia or atrial fibrillation (AT/AF) recurrence has been studied. However,
the long-term correlation of symptoms with continuous monitoring of AT/AF episodes dur-
ing pacing is unknown.
Methods: This prospective multicenter trial assessed the development of AT/AF in paced
patients by examining the correlation of patient-reported symptoms with device-detected
AT/AF event data in patients with bradyarrhythmias and > 1 episode of AT/AF in the prior
year. Full disclosure device datalogs with electrogram (EGM) validation of AT/AF events
were obtained from a pacemaker (AT500, Medtronic) that records the daily frequency,
atrial and ventricular cycle length, EGM, and duration of AT/AF episodes. Patients logged
symptomatic events into the device memory via an external manual activator. Following a
one-month lead-in period, patients were followed for an additional 12 months and were
contacted weekly to ensure compliance with activator usage. Episodes were classified as
symptomatic AT/AF, asymptomatic AT/AF, or symptomatic “non-AT/AF” depending on
concordance between patient-indicated symptoms and device-detected AT/AF.
Results: 48 patients (28 M, 76±10 yr) were implanted and followed for 12±2 months.
Arrhythmia-related symptoms were noted in 8% of all device-detected AT/AF episodes
(sensitivity).Only 19% of all patient symptoms were associated with device documented
AT/AF events (positive predictive value). A paired analysis in a subset of patients (n=15)
with both symptomatic and asymptomatic stored episodes indicated no difference
(p=NS) with respect to median ventricular rate (94 vs 94 bpm), atrial cycle length (230 vs
235 ms), or episode duration (103 vs 75 s).
Conclusion: Over a long-term follow-up, the vast majority of AT/AF episodes are asymp-
tomatic and patient symptoms are seldom associated with AT/AF episodes. Hence,
patient symptoms are an unreliable index of recurrent AF in clinical studies of AF thera-
pies and in management of anticoagulation therapy. Continuous monitoring via implant-
able device datalogs provides objective early and reliable detection of AF during follow-
up.
1166-210 Silent Atrial Fibrillation: An Important Contributor to 
Total Burden of Atrial Fibrillation in Olmsted County, MN 
(1980-1989)
Marion E. Barnes, Yoko Miyasaka, A. Gabriela Rosales, Kent R. Bailey, James B. 
Seward, Bernard J. Gersh, Teresa S.M. Tsang, Mayo Clinic, Rochester, MN
Background: There is a paucity of data on “silent” atrial fibrillation (AF). In this study, we
aimed to estimate the prevalence of AF discovered incidentally in asymptomatic patients.
Methods: The medical records for all adult residents of Olmsted County, MN, who had an
ECG-confirmed diagnosis of first AF during 1980-89 were reviewed. Symptom presenta-
tion was classified as typical for AF, non-specific (symptoms present, but not classic for
AF), or 'silent' (asymptomatic, AF detected incidentally).
Results: A total of 801 (412 men, 389 women) residents (mean age, 72 ± 14 years, range
18-103 years) were documented to have the first episode of AF between 1980 and 1989.
After exclusion of patients (n=186, 23%) with concurrent conditions that could have
obscured AF symptoms (recent myocardial infarction (MI) or congestive heart failure
(CHF)), and those in whom symptom data were not available (n=59, 7%), silent AF was
identified in 193 (24%). The remaining 363 patients had symptoms at presentation (typi-
cal, n=186; non-specific symptoms, n=177). Clinical characteristics of those with silent
AF versus those who presented with symptoms are detailed (Table). In a multivariate
model, age (P<0.001), male gender (P=0.007), slower AF rate (P<0.001), and history of
MI(P=0.028) were independently related to silent AF.
Conclusion: 'Silent' AF accounts for a significant proportion of the total AF burden. Future
studies to elucidate the outcomes for this subgroup of AF patients will be of immense
public health importance.
1166-211 Magnesium Effectively Prevents Postoperative Atrial 
Fibrillation in Patients After Heart Surgery: Meta-
Analysis of Randomized Trials on 2,040 Patients
Eugene Crystal, Saul Miller, Michael Garfinkle, Stuart Connolly, Ching Lau, Schulich 
Heart Center, University of Toronto, Toronto, ON, Canada, McMaster University, 
Hamilton, ON, Canada
Background: Atrial fibrillation is a frequent and clinically important complication of heart
surgery. Magnesium has been evaluated as a method of prophylaxis for the prevention of
postoperative atrial fibrillation in a number of small trials with inconsistent results.
Methods: A literature search and meta-analysis of the randomized control studies pub-
lished since 1966 was performed using the Cochrane methodology.
Results: Eighteen randomized trials were identified, enrolling a total of 2040 patients.
Study sample size varied between 20 and 200 patients. Magnesium administration
decreased the proportion of patients developing postoperative atrial fibrillation from 28%
in the control group to 17% in the treatment group (odds ratio 0.51; 95% Confidence
interval, 0.34 to 0.76). Data on length of stay was available from 6 trials (827 patients).
Magnesium did not have a significant effect on length of stay (weighted mean difference -
0.07 days of stay, 95% Confidence interval -0.78, 0.63). The overall mortality was low
(0.7%), and was not affected by magnesium administration (odds ratio 0.90, 95%CI 0.24;
3.32).
Conclusion: Magnesium administration is an effective prophylactic measure for the pre-
vention of postoperative atrial fibrillation. The magnitude of the effect of magnesium is
similar to this of beta-blockers or amiodarone. Magnesium does not affect significantly
length of stay or in-hospital mortality.
1166-212 Pulmonary Vein Isolation in Patients With Prior Cardiac 
Surgery
Raed H. Abdelhadi, Jennifer Cummings, Oussama Wazni, Marc Gillinov, Andrea Natale, 
Nassir F. Marrouche, Cleveland Clinic Foundation, Cleveland, OH
Background:
Pulmonary vein isolation (PVI) has become a treatment option for patients with symptom-
atic atrial fibrillation (AF) resistant to medical therapy. The outcome of this procedure in
patients who developed AF after cardiac surgery has not been established.
Methods:
Out of 454 patients who had PVI for symptomatic AF resistant to antiarrhythmic medica-
tion, we identified 36 patients with prior cardiac surgery who subsequently underwent
PVI. The baseline characteristics and the recurrence rate in patients with prior cardiac
surgery to the rest of the cohort.
Results:
Patients with cardiac surgery did not differ in their age (58 ± 10 vs. 54 ± 12 years), dura-
tion of AF (6.2 ± 3.2 vs. 5.9 ± 4.3 years), and length of follow up after PVI (456 ± 187 vs.
515±192 days). Patients with prior cardiac surgery had larger left atrial diameter (4.8 ±
1.2 vs. 4.1 ± 0.5 cm, P = 0.02), and lower left ventricular ejection fraction (47 ± 14 vs. 54
± 11 %, P = 0.03). There was no significant difference in AF recurrence in patients with
prior cardiac surgery compared to the rest of the cohort (11% vs. 18%, P = 0.9). Neither
ejection fraction nor left atrial size predicted recurrence of AF.
Conclusion:
From our preliminary data, PVI seems to be feasible and effective even in patients with
prior cardiac surgery. Therefore, history of cardiac surgery should not be considered an
exclusion criterion for this procedure. 
Subjects with U Wave in Lead V5
Non-Carriers (n) LQT1 Carriers (n) LQT2 Carriers (n)
All Subjects 48% (215) 44% (87) 37% (134)
QTc<470ms 49% (204) 59% (29) 59% (42)
QTc=>470ms 36% (11) 35%* (57) 27%* (92)
Numbers in parentheses represent number of patients in each category
* p470ms vs. <470ms
Baseline Characteristics Silent AF
(N=208)
Symptomatic 
presentation 
(N=534)
P value
Age, years 75 ± 12 70 ± 16 <0.001
Male, No (%) 105(54) 176 (48) 0.18
ECG heart rate at incident AF documentation, 
bpm
104 ± 30 120 ± 32 <0.001
Systolic blood pressure, mm Hg 143 ± 21 141 ± 21 0.16
Diastolic blood pressure, mm Hg 81 ± 10 79 ± 10 0.07
History of MI, No (%) 12 (6) 36 (10) 0.14
Hypertension, No (%) 159 (82) 273 (75) 0.05
History of CHF, No (%) 27 (14) 29 (8) 0.025
Stroke or transient ischemic attack, No (%) 33 (17) 47 (13) 0.18
